Typhoid Fever Vaccines

Typhoid Fever Vaccines Market Outlook

The global Typhoid Fever Vaccines Market is projected to reach approximately $1.2 billion by 2035, registering a robust compound annual growth rate (CAGR) of around 5% during the forecast period from 2025 to 2035. This growth is primarily driven by the increasing incidence of typhoid fever, particularly in developing countries, alongside rising awareness regarding preventive healthcare measures. Furthermore, advancements in vaccine technology and ongoing research to improve the efficacy and safety profile of vaccines are expected to contribute significantly to market expansion. The strategic initiatives by healthcare governments and organizations to eradicate typhoid fever, coupled with a surge in vaccination programs in endemic regions, will also bolster the market's growth trajectory. Additionally, the increasing focus on immunization in children and travelers to high-risk areas is poised to create a favorable environment for market players.

Growth Factor of the Market

The Typhoid Fever Vaccines Market is poised for growth due to several pivotal factors. First and foremost, the rising number of reported typhoid fever cases globally has underscored the urgent need for effective vaccination strategies. The World Health Organization (WHO) has identified typhoid fever as a significant public health concern, particularly in low- and middle-income countries, which drives governmental and NGO efforts to enhance vaccination coverage. Furthermore, the increasing rate of travel to endemic regions has heightened awareness among travelers about the risks associated with typhoid fever, thereby propelling the demand for vaccines. Another critical aspect is the technological advancements in vaccine development, leading to the introduction of more effective and longer-lasting vaccines. Lastly, the global emphasis on preventive healthcare and the push for immunization programs in schools and community health initiatives are pivotal trends that are expected to further stimulate market growth.

Key Highlights of the Market

• The market is expected to grow at a CAGR of 5% from 2025 to 2035.
• Increasing incidence of typhoid fever in developing countries remains a significant growth driver.
• Technological advancements in vaccine development are enhancing efficacy and safety.
• Government initiatives for vaccination coverage are gaining momentum.
• Rising awareness among travelers about typhoid risks is driving vaccine demand.

By Product Type

Live Attenuated Vaccines:

Live attenuated vaccines are among the most effective means of preventing typhoid fever. These vaccines contain a weakened form of the Salmonella Typhi bacteria, which induces an immune response without causing the disease. The significant advantage of live attenuated vaccines is their ability to provide long-lasting immunity with a single dose, which is particularly beneficial in regions with high endemicity. Furthermore, these vaccines have shown effectiveness in both children and adults, making them suitable for widespread immunization campaigns. The increased focus on immunization programs in endemic areas is driving the demand for live attenuated vaccines, thus positioning them prominently within the market landscape.

Conjugate Vaccines:

Conjugate vaccines, which link the polysaccharide from the bacteria to a protein carrier, are gaining traction in the Typhoid Fever Vaccines Market due to their impressive immunogenicity and the ability to elicit a strong immune response in infants and young children. These vaccines tend to have fewer side effects and can be administered alongside routine childhood vaccinations, making them an attractive option for healthcare providers. The growing implementation of childhood immunization programs and recommendations from health authorities to include conjugate vaccines in their schedules further support market growth in this segment. Additionally, advancements in production technology are expected to enhance accessibility and affordability, thereby reinforcing market presence.

Subunit Vaccines:

Subunit vaccines are formulated using specific pieces of the pathogen, such as proteins or sugars, rather than the whole pathogen, which reduces the risk of adverse reactions. This type of vaccine has a favorable safety profile, making it a suitable option for broader population groups, including those with compromised immune systems. The increasing focus on developing safer vaccines has led to a rise in research and development initiatives aimed at enhancing the efficacy of subunit vaccines against typhoid. The potential to combine subunit vaccines with other immunizations in a multi-valent vaccine format is also being explored, which could substantially elevate their market share in the coming years.

Inactivated Vaccines:

Inactivated vaccines, which contain killed bacteria, are an established method for typhoid prevention. These vaccines are well-researched and have been administered for many years, resulting in a robust safety profile. Despite a slightly lower efficacy compared to live attenuated vaccines, their broad acceptability and reliability make them a staple in vaccination programs, particularly in regions where typhoid fever is prevalent. The demand for inactivated vaccines remains steady, supported by ongoing public health initiatives aimed at reducing typhoid incidence. Additionally, their compatibility with existing vaccination schedules enhances their appeal among healthcare providers and patients alike.

Others:

This category includes various innovative vaccine formulations that are in the pipeline or have limited availability in the market. Research efforts are underway to develop novel vaccines that utilize different mechanisms or novel delivery systems, such as mRNA technology. These upcoming products aim to enhance immune response and provide broader protection against typhoid fever. Furthermore, the potential for combination vaccines that can target multiple pathogens may also drive interest in this segment. As research and development continue to evolve, these 'other' vaccines have the potential to carve out a significant niche in the Typhoid Fever Vaccines Market.

By Application

Hospitals:

Hospitals play a critical role in administering typhoid fever vaccines, particularly in areas where the disease is endemic. The demand for vaccines in hospitals is driven by the influx of patients seeking treatment and preventive measures, especially during outbreaks. Hospitals are equipped with the necessary infrastructure and trained personnel to handle vaccination campaigns efficiently, ensuring that vaccines are administered safely and effectively. Furthermore, hospitals often collaborate with government health initiatives to provide vaccinations to at-risk populations, which enhances their visibility and accessibility. As hospitals continue to be pivotal in public health efforts, the demand for typhoid fever vaccines in this sector is expected to grow consistently.

Clinics:

Clinics, including community health centers and primary care facilities, are essential for increasing access to typhoid fever vaccines, particularly for individuals who may not seek care in hospitals. These smaller healthcare settings often provide vaccines as part of routine check-ups or preventive health screenings, thereby enhancing awareness of typhoid fever risks. The convenience and accessibility of clinics make them an ideal venue for vaccination campaigns, particularly in urban and rural areas that may be underserved by larger healthcare institutions. The ongoing emphasis on preventive healthcare and community outreach programs further supports the increasing role of clinics in administering typhoid vaccines.

Research Institutes:

Research institutes contribute to the Typhoid Fever Vaccines Market by conducting critical studies that lead to the development of new vaccines and improved formulations. These institutes are often involved in clinical trials, evaluating the safety and efficacy of new vaccine candidates, and providing valuable data to regulatory authorities. The insights generated from research activities inform public health policies and vaccination strategies, which are essential for controlling the spread of typhoid fever. The collaboration between research institutes and vaccine manufacturers fosters innovation and drives advancements in vaccine development, thus playing a significant role in the overall growth of the market.

Others:

The 'Others' category in applications encompasses a variety of settings where typhoid fever vaccines may be administered, including mobile clinics, immunization drives in schools, and outreach programs in rural areas. These alternative venues enhance the reach of vaccines to populations that may be hesitant or unable to access traditional healthcare facilities. The flexibility and adaptability of mobile vaccination units, in particular, allow for targeted immunization campaigns in high-risk communities, significantly contributing to the reduction of typhoid fever incidences. Additionally, collaborations with non-governmental organizations (NGOs) and international health agencies further bolster vaccination efforts in these diverse environments.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies serve as a crucial distribution channel for typhoid fever vaccines, ensuring that vaccines are readily available to patients in need. These pharmacies are often located within hospitals, allowing for the seamless integration of vaccination services with other healthcare provisions. As hospitals frequently deal with patients at high risk of typhoid fever, the demand for vaccines through hospital pharmacies continues to remain strong. Moreover, the convenience of receiving vaccinations during hospital visits encourages more patients to get vaccinated, thereby increasing overall immunization rates. The collaboration of hospital pharmacies with local health departments further enhances the distribution and accessibility of vaccines.

Retail Pharmacies:

Retail pharmacies play a significant role in the Typhoid Fever Vaccines Market by providing easy access to vaccines for the general population. With a growing focus on preventive healthcare, many retail pharmacies offer vaccination services, allowing individuals to receive their typhoid vaccine conveniently while running errands. The increasing number of partnerships between pharmacies and healthcare systems has facilitated training for pharmacy staff, enabling them to administer vaccines safely and effectively. Retail pharmacies' extensive reach and accessibility make them a vital channel for increasing vaccination coverage, particularly among travelers and those living in endemic areas.

Online Pharmacies:

Online pharmacies are emerging as a convenient distribution channel for typhoid fever vaccines, particularly in light of the growing trend towards digital healthcare services. The accessibility of online platforms allows individuals to order vaccines and receive them either via mail or through local pharmacy pick-up options. The convenience of obtaining vaccines online has been particularly appealing during the COVID-19 pandemic, as many consumers have shifted to online shopping for their healthcare needs. While regulatory and logistical challenges exist, the potential for online pharmacies to enhance vaccine distribution remains significant, particularly in regions with limited access to traditional healthcare facilities.

Others:

This category encompasses various alternative distribution channels for typhoid fever vaccines, such as government health initiatives, community outreach programs, and non-profit organizations that facilitate vaccine delivery to underserved populations. These alternative channels are crucial for reaching individuals who may not have access to traditional healthcare frameworks. Many governments and NGOs run vaccination drives in schools, community centers, and remote areas, ensuring that vaccines reach high-risk populations effectively. The growing emphasis on public health measures and community engagement further supports the utilization of these diverse distribution channels, enhancing overall vaccination coverage and reducing the incidence of typhoid fever.

By Ingredient Type

Ty21a:

Ty21a is a live attenuated oral vaccine that has been widely utilized in typhoid vaccination programs. This vaccine is particularly effective in stimulating an immune response and has shown robust efficacy against typhoid fever in various clinical trials. The oral administration method improves patient compliance compared to injectable vaccines, making it a popular choice among healthcare providers. With the increasing prevalence of typhoid fever in several regions, Ty21a's ease of administration and effectiveness contribute to its sustained demand in the market. Future research and development efforts are expected to enhance its application in mass immunization campaigns further.

Vi Polysaccharide:

The Vi polysaccharide vaccine is another effective option for providing immunity against typhoid fever. This vaccine contains purified polysaccharides from the capsule of the Salmonella Typhi bacteria, stimulating an immune response without causing the disease. The Vi polysaccharide vaccine is particularly advantageous due to its long shelf life and stability, which facilitates its handling and storage in various healthcare settings. As a result, it is frequently included in vaccination programs in endemic areas. The ongoing development of improved formulations and the potential for combination vaccines are expected to further bolster the market share of Vi polysaccharide vaccines.

Conjugate Vi Vaccines:

Conjugate Vi vaccines have emerged as a promising advancement in typhoid prevention, particularly for young children. By combining the Vi polysaccharide with a carrier protein, these vaccines enhance the immune response, making them suitable for infants and toddlers. The increasing focus on ensuring that children are adequately vaccinated against preventable diseases drives the demand for conjugate vaccines. Additionally, as health authorities emphasize the importance of child immunization, conjugate Vi vaccines are likely to gain traction in vaccination schedules worldwide. Ongoing research will undoubtedly lead to further improvements in these vaccines, enhancing their market presence.

Others:

The 'Others' category includes various innovative ingredients and formulations that are in development, aimed at improving the efficacy and safety of typhoid vaccines. Ongoing research is exploring novel adjuvants and delivery mechanisms that could enhance immune responses or reduce the number of doses required for effective immunity. As new scientific advancements emerge, particularly in biotechnology and immunology, these innovative ingredients have the potential to revolutionize typhoid vaccination strategies, impacting the overall market landscape. The continual search for more effective and patient-friendly vaccine options will likely drive significant growth in this segment as well.

By Region

The Typhoid Fever Vaccines Market is segmented into various regions, with each region showing unique characteristics in terms of prevalence, vaccination efforts, and market dynamics. North America and Europe are witnessing a steady demand for typhoid vaccines, primarily driven by travel-related cases and increased awareness of preventable diseases. In these regions, the focus is on maintaining herd immunity and protecting vulnerable populations, contributing to a modest yet stable market growth rate. In contrast, the Asia Pacific region, which has the highest incidence of typhoid fever, is expected to experience robust growth, with a projected CAGR of approximately 6% during the forecast period. This surge can be attributed to increased public health initiatives, government support for vaccinations, and a growing emphasis on preventive healthcare in high-risk communities.

Latin America and the Middle East & Africa regions exhibit a contrasting landscape, where the incidence of typhoid fever remains a significant concern. Countries in these regions are actively seeking to enhance vaccination programs to combat the disease, leading to accelerated market growth. In particular, regions with significant outbreaks or endemic patterns are prioritizing vaccine access and education, further driving demand. As healthcare infrastructure improves and public awareness increases, the Typhoid Fever Vaccines Market in these regions is expected to expand substantially. Overall, while North America and Europe focus on maintaining existing vaccination efforts, the real growth potential lies within the Asia Pacific and Latin America regions, where public health initiatives are adapting to combat typhoid fever effectively.

Opportunities

The Typhoid Fever Vaccines Market presents numerous opportunities for both established companies and emerging players. One significant opportunity lies in the advancing technology for vaccine development, such as recombinant and mRNA vaccine platforms. These innovative technologies can improve vaccine efficacy, safety, and delivery methods, attracting more individuals to vaccination programs. As public health systems continue to evolve, there is also an increased focus on the integration of vaccination into routine healthcare services. This opens up avenues for partnerships between pharmaceutical companies and healthcare providers to expand vaccine access and affordability, particularly in underserved regions where typhoid fever remains a critical public health threat. The potential for combination vaccines that target multiple diseases can also create new market opportunities, as healthcare providers seek comprehensive solutions to protect their patients.

Moreover, the ongoing global focus on pandemic preparedness highlights the importance of robust vaccination programs. Governments and health organizations are likely to invest more resources into preventing diseases like typhoid fever, which can have severe health implications in populations with limited access to healthcare. Public awareness campaigns and collaborations with non-governmental organizations (NGOs) can further strengthen vaccination efforts, particularly in areas most affected by typhoid fever. As the demand for vaccines continues to rise, there is a growing need for innovative distribution methods, such as mobile vaccination units or online pharmaceutical platforms, that can reach remote or high-risk populations effectively. Overall, the market is ripe with opportunities for innovation and collaboration, enhancing both public health outcomes and business growth.

Threats

While the Typhoid Fever Vaccines Market is poised for growth, several threats could hinder its progress. One of the most significant threats is the emergence of antibiotic-resistant strains of Salmonella Typhi, which pose a challenge to existing treatment and prevention methods. The rising prevalence of multi-drug-resistant typhoid fever cases has underscored the urgent need for novel vaccines and treatments. Additionally, vaccine hesitancy among certain populations can significantly impact immunization rates, as misinformation and distrust in healthcare systems lead to lower vaccine uptake. This reluctance to vaccinate can result in outbreaks and increase the burden of disease, undermining efforts to control typhoid fever spread.

Moreover, logistical challenges in vaccine distribution, particularly in low-resource settings, can hinder access to vaccines. Issues such as inadequate cold chain infrastructure, lack of trained personnel, and financial constraints can limit the effectiveness of vaccination campaigns, particularly in rural or underserved areas. Additionally, geopolitical factors and conflicts can disrupt healthcare systems, making it difficult to deliver essential vaccines to populations at risk. As the market navigates these challenges, it is crucial for stakeholders to develop adaptive strategies that can mitigate these threats and ensure robust vaccination coverage to combat typhoid fever effectively.

Competitor Outlook

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Pfizer
• Merck & Co., Inc.
• Serum Institute of India
• Indian Immunologicals
• VBI Vaccines Inc.
• Panacea Biotec
• Novavax, Inc.
• Emergent BioSolutions Inc.
• Hualan Biological Engineering Inc.
• BioNet-Asia
• Inovio Pharmaceuticals Inc.
• Bharat Biotech
• Advent BioServices

The competitive landscape of the Typhoid Fever Vaccines Market is characterized by several established pharmaceutical companies and emerging biotech firms striving to innovate and enhance vaccine offerings. Major players, such as Sanofi Pasteur and GlaxoSmithKline, dominate the market due to their extensive research and development capabilities, strong distribution networks, and established brand recognition. These companies have made significant investments in vaccine research to improve their product lines, focusing on efficacy, safety, and accessibility, thereby solidifying their market positions. The competition is further heightened by the rapid development of novel vaccine technologies, prompting companies to continuously innovate to stay ahead in a dynamic market environment.

In addition to established players, a range of emerging biotech firms is actively entering the Typhoid Fever Vaccines Market, focusing on novel formulations and delivery systems. Companies like VBI Vaccines and Inovio Pharmaceuticals are leveraging cutting-edge research in immunology and biotechnology to develop next-generation vaccines. These innovative players are often agile and can quickly respond to new market opportunities or challenges, making them formidable competitors. Furthermore, collaborations between pharmaceutical companies and research institutions are becoming increasingly common, fostering an environment of shared expertise and resources that can accelerate the development of effective vaccines.

Key players in the market, such as Bharat Biotech and the Serum Institute of India, have been instrumental in making typhoid vaccines more accessible in developing regions. Their efforts in scaling production capacity and ensuring affordability play a crucial role in public health initiatives aimed at combating typhoid fever. Additionally, some companies are exploring the possibility of combination vaccines that target multiple infectious diseases, which can enhance vaccine uptake and provide more comprehensive protection. As the market evolves, the competitive landscape will continue to shift, driven by advancements in vaccine technology, regulatory changes, and the need for effective prevention strategies against typhoid fever.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Pfizer
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 BioNet-Asia
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novavax, Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Bharat Biotech
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Panacea Biotec
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Sanofi Pasteur
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Merck & Co., Inc.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 VBI Vaccines Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Advent BioServices
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 GlaxoSmithKline (GSK)
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Indian Immunologicals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Serum Institute of India
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Emergent BioSolutions Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Inovio Pharmaceuticals Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Hualan Biological Engineering Inc.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Typhoid Fever Vaccines Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Research Institutes
    • 6.1.4 Others
  • 6.2 Typhoid Fever Vaccines Market, By Product Type
    • 6.2.1 Live Attenuated Vaccines
    • 6.2.2 Conjugate Vaccines
    • 6.2.3 Subunit Vaccines
    • 6.2.4 Inactivated Vaccines
    • 6.2.5 Others
  • 6.3 Typhoid Fever Vaccines Market, By Ingredient Type
    • 6.3.1 Ty21a
    • 6.3.2 Vi Polysaccharide
    • 6.3.3 Conjugate Vi Vaccines
    • 6.3.4 Others
  • 6.4 Typhoid Fever Vaccines Market, By Distribution Channel
    • 6.4.1 Hospitals Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Typhoid Fever Vaccines Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Typhoid Fever Vaccines market is categorized based on

By Product Type

• Live Attenuated Vaccines
• Conjugate Vaccines
• Subunit Vaccines
• Inactivated Vaccines
• Others

By Application

• Hospitals
• Clinics
• Research Institutes
• Others

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Ty21a
• Vi Polysaccharide
• Conjugate Vi Vaccines
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Sanofi Pasteur
• GlaxoSmithKline (GSK)
• Pfizer
• Merck & Co., Inc.
• Serum Institute of India
• Indian Immunologicals
• VBI Vaccines Inc.
• Panacea Biotec
• Novavax, Inc.
• Emergent BioSolutions Inc.
• Hualan Biological Engineering Inc.
• BioNet-Asia
• Inovio Pharmaceuticals Inc.
• Bharat Biotech
• Advent BioServices